Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-02-28

FDA Approved: PANCREAZE — Supplemental Application (VIVUS LLC)

View source ↗

Summary

FDA approved a supplemental application for PANCREAZE, a pancreatic enzyme replacement product, submitted by VIVUS LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Pancreaze (pancrelipase)

Snippet

SUPPL AP for PANCREAZE (PANCRELIPASE LIPASE, PANCRELIPASE AMYLASE, AND PANCRELIPASE PROTEASE)